ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1560

Glomerular Diseases in Flanders: Overview of the FCGG Biopsy Registry

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Deleersnijder, Dries, Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Flanders, Belgium
  • Laurens, Wim, AZ Nikolaas, Sint-Niklaas, Oost-Vlaanderen, Belgium
  • De Meester, Johan MJ, AZ Nikolaas, Sint-Niklaas, Oost-Vlaanderen, Belgium
  • Dendooven, Amélie, Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen, Belgium
  • Sprangers, Ben, Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Flanders, Belgium
Background

High-quality population-based registries on glomerular diseases are required for epidemiological study and new trial design. The FCGG (Flemish Collaborative Glomerulonephritis Group) database is a population-based registry that has been including data on all native kidney biopsies performed in Flanders since 2017 (Northern part of Belgium) covering a population of approximately 6.5 million inhabitants.

Methods

Clinical data and nephrological diagnosis according to the ERA-EDTA Coding system for Primary Renal Disease are collected together with pathological data including primary and secondary pathological diagnoses according to the Mayo Clinic/Renal Pathology Society Consensus Guideline 2016. Here, we describe the main results of the first three years of the registry.

Results

From 2017 until 2019, 2178 biopsies were included, of which 5.7% were performed in the pediatric population. Median age (IQR) was 59 years (42-71). Biopsy incidence proportion was 130 biopsies p.m.p. per year in the adult population. Glomerular disease was present in 54% of the adult biopsies (Fig. 1A). IgA-nephropathy (IgAN) was the most frequently diagnosed disease in adults (17.3% of total, 30.2% of glomerular subcategory). The etiologies of the nephrotic syndrome differed across age categories, with membranous nephropathy (MN) being most frequently diagnosed in the total group of adult nephrotic patients (Fig. 1B). IgAN and pauci-immune glomerulonephritis (AAV) were the two most important causes of the nephritic syndrome in adults. A crescentic pattern of injury was most frequently diagnosed in adults with AAV, lupus nephritis (LN) and IgAN (Fig. 1C, crescents in 82%, 31% and 24% of biopsies, respectively).

Conclusion

The FCGG database is a valuable population-based registry that characterizes the epidemiology of glomerular disease in Flanders. These results are relevant to the clinician, will enable disease subgroup analyses and are useful to set up observational or interventional trials in patients with glomerular disease.